Karim Fizazi, MD, PhD | Authors


Achieving MFS and Improved Quality of Life in nmCRPC With Darolutamide

July 16, 2019

Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer, recently presented during the 2019 ASCO Annual Meeting.